GSM城市站国家站国际

FDA批准首款可在家使用的激越治疗药:Teva的IGALMI舌下膜片获批用于精神分裂症与双相障碍成人

2026-11-16 · 医疗 · GSM News
FDA批准首款可在家使用的激越治疗药:Teva的IGALMI舌下膜片获批用于精神分裂症与双相障碍成人

Teva Pharmaceuticals 11月16日宣布,美国食品药品监管局(FDA)已批准其 IGALMI(右美托咪定)舌下膜片用于居家使用。该药由此成为首款获 FDA 批准、可以在家中用于成人精神分裂症、分裂情感性障碍或双相 I 型、II 型障碍相关激越急性发作的治疗。

激越是上述疾病常见的急性症状,患者会出现紧张、不安与活动增多,发作可能迅速升级。据 Teva 介绍,激越影响相关患者中的 25% 至 40%,多达 21% 的发作最终需要急诊就诊或住院。此前,获批的激越治疗一般要在医疗机构内、或在医护人员监督下使用,患者在家中发作时没有可自行使用的获批药物。

这次批准依据三期 SERENITY 居家安全性与耐受性试验的结果。该试验为随机、双盲、安慰剂对照设计,为期 12 周,102 名患者共 1,160 次激越发作接受了 IGALMI 治疗,试验达到安全性与耐受性主要终点,重复给药期间的耐受性保持一致,没有患者因耐受性问题停药。最常报告的不良反应包括嗜睡、口干、头晕,以及口腔感觉异常或口腔感觉减退。

Teva 美国商业执行副总裁 Chris Fox 表示,这款首个获批的居家激越治疗给患者与照护者提供了一个在发作发生地点处理症状的新选项。Teva 全球研发执行副总裁兼首席医学官 Eric Hughes 表示,能在症状刚出现时就进行治疗,为患者与照护者管理这类发作提供了重要的新方式。

Teva 于 2026 年 10 月下旬收购了 IGALMI。这次居家使用的补充新药申请于 2026 年 1 月 14 日提交,是在该药原先获批的医护监督使用基础上提出的。Teva 表示,IGALMI 居家使用的商业化计划将在稍后公布。

(来源:Teva)

FDA Approves IGALMI as First At-Home Treatment for Agitation Associated With Schizophrenia and Bipolar Disorder in Adults

Teva Pharmaceuticals announced on November 16 that the U.S. Food and Drug Administration (FDA) has approved IGALMI (dexmedetomidine) sublingual film for at-home use. With the approval, IGALMI becomes the first FDA-approved treatment that can be used at home for acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults.

Agitation is a common acute symptom of these conditions, marked by tension, restlessness and increased activity, and episodes can escalate quickly. According to Teva, agitation affects between 25% and 40% of patients across these conditions, and in up to 21% of cases an episode results in an emergency department visit or hospitalization. Until now, approved treatments generally had to be given in a healthcare setting or under the supervision of a healthcare provider, leaving patients without an approved option they could use themselves when an episode occurred at home.

The approval is supported by the Phase 3 SERENITY At-Home Safety and Tolerability Trial, a randomized, double-blind, placebo-controlled 12-week study in which 1,160 agitation episodes in 102 patients were treated with IGALMI. The trial met its primary endpoint of safety and tolerability in the at-home setting, tolerability remained consistent with repeat dosing, and there were no discontinuations due to tolerability. The most commonly reported adverse events were somnolence, dry mouth, dizziness, and oral paresthesia or oral hypoesthesia.

Chris Fox, Executive Vice President, U.S. Commercial and Head of Innovative Franchise at Teva, said the first FDA-approved at-home treatment for agitation associated with these conditions gives patients and caregivers an important new option in the setting where episodes often occur. Eric Hughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief Medical Officer at Teva, said being able to treat agitation symptoms when they start gives patients and caregivers an important new way to manage these episodes.

Teva acquired IGALMI in late October 2026. The application for at-home use was submitted on January 14, 2026, as a supplemental New Drug Application building on the product's existing approval for use under healthcare provider supervision. Teva said it will announce commercialization plans for IGALMI for at-home use at a later date.

(Source: Teva)

来源:Teva

发布:GSM·美国(发布链接)

图片来源:图:美国食品药品监管局(FDA)总部大楼入口。FDA 官方图,公共领域,经 Wikimedia Commons。 / Photo: Entrance of the U.S. Food and Drug Administration headquarters. FDA official photo, public domain, via Wikimedia Commons.

GSM Global · 本篇英文版 English edition of this story

本频道最新更多 ›

← 返回医疗 全部新闻 关于我们

GSM首页白宫联邦加州南加各州社会军事司法选举世界中国城市站国家站移民宣传专题视频直播放映厅电子书电子报科技金融教育医疗影视音乐体育文旅时尚演出活动娱乐游戏生活美食户外交通汽车地产保险儿童长者留学生宠物信仰非盈利机构